We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARADIGM CORP. ARDM -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (220)9/28/2004 11:41:48 PM
From: rkrw  Read Replies (1) | Respond to of 255
What will ardm invest in now?

To: keokalani'nui who wrote (220)9/28/2004 11:54:20 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 255
Wow. All sorts of strange and good news of late, strange developments. Fun.

To: keokalani'nui who wrote (220)10/13/2004 2:49:58 PM
From: tuck  Respond to of 255
>>HAYWARD, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Aradigm Corporation (Nasdaq: ARDM - News) today announced positive results from the Clinical Performance Verification (CPV) Trial of its Intraject needle-free delivery system. Results from the trial showed that the study met its primary endpoint of demonstration of successful injection performance with Intraject with an excellent reliability profile.

The trial demonstrated acceptable performance and delivery consistency of the selected configuration in 194 healthy subjects who were each given multiple injections of saline via Intraject. In total, there were 1152 injections with no occurrence of injection-related adverse events and no reliability issues such as glass breakage or malfunctions. Subjects rated their injections as causing little or no pain sensation, a result in line with numerous other studies previously conducted with Intraject. In addition, the majority of subjects responded that they preferred the use of the Intraject device to a standard needle injection.

"This trial was the final stage of technical development for Intraject and clearly demonstrates that the technological and design issues that faced the system prior to our acquisition of the Intraject technology have been fully addressed," said Dr. Bryan Lawlis, President and Chief Executive Officer of Aradigm. "The CPV data and extensive reliability testing conducted on the final Intraject configuration in parallel with this study exceed the performance requirements for Intraject. In addition, we have made excellent progress with our contract manufacturers towards process scale-up for registration and commercial manufacturing. This strong technical foundation lets us initiate the partnering of the platform to companies for use with their drugs, as well as allowing us to commence clinical trials using Intraject with a drug of our own choosing. We expect to complete and announce the selection of the drug by the end of the year with the objective of commencing pivotal trials for regulatory submissions in the second half of next year."<<


Cheers, Tuck

To: keokalani'nui who wrote (220)12/2/2004 11:25:44 AM
From: Tadsamillionaire  Respond to of 255
Corporation (NASDAQ: ARDM) announced today that Dr. Bryan Lawlis,
President and Chief Executive Officer will present at the Robins
Small-Cap Life Sciences Investor Conference in New York on December 7,

Dr. Lawlis is scheduled to present at 1:15 p.m. EST at the Lotus
Club, located at 5 East 66th Street.

This conference presentation is being webcast and can be accessed

The Robins Small-Cap Life Sciences Conference will feature
small-cap life sciences companies expected to perform well in 2005.

Bradley Pharmaceuticals, Inc. kicks off the conference at 9:00
a.m. EST. Other presenting companies include Cardiotech International,
Inc., LifePoint, Inc., and Curon Medical, Inc..

The conference is open, free of charge, to the professional
investment community and will be moderated by Marc Robins, CFA,
founder of The Robins Group (an Institutional Broker Dealer) and
Robins Media.

About Robins Media:

Marc Robins has over 25 years of experience in the small-cap
arena, including a regularly featured column in Forbes, contributing
articles in the AAII Journal and his frequent quotes found in various
financial media. The conference is part of a series of events hosted
by Robins Media. These events showcase undervalued, under-followed
small-cap companies.

About Aradigm Corporation

Aradigm develops non-invasive delivery systems to enable patients
to comfortably self-administer biopharmaceuticals and small molecules
that would otherwise be given by injection. The company's advanced
AERx(R) pulmonary and Intraject(R) needle-free delivery technologies
offer rapid delivery solutions for liquid drug formulations. Current
development programs focus on neurological disorders, heart disease,
respiratory conditions and cancer. More information about Aradigm can
be found at